One Health

One Health is an emerging health-tech startup.

Led by a team that’s achieved more than five billion dollars’ worth of exits, this company is targeting the ten-billion-dollar market for diabetes management.

Thirty-six million Americans have Type 2 diabetes. Yet more than ninety percent of them don’t have affordable access to a continuous glucose monitor (CGM), a wearable device that tracks blood sugar levels in real-time — people like Jim, for example.

Jim has Type 2 diabetes and doesn’t want to start using insulin. He’s willing to adjust his lifestyle, but needs help getting started.

His doctor suggests starting on a CGM, which will help Jim understand what impacts his blood sugar and make the right decisions to improve his health. The problem is that Jim’s insurance doesn’t reimburse for CGM and he wants to know how much this will cost.

Currently, his options are expensive. The CGM market is dominated by two players — FreeStyle Libre2 and DexCom — both of whom have achieved considerable success. FreeStyle has five-and-a-half million users and generated $1.4 billion in Q4 2023 revenue. Dexcom has more than two million users and generated a billion dollars in Q4 2023 revenue.

FreeStyle offers a CGM that is disposable after fourteen days. But this system involves the purchase of applicators, batteries, and transmitters for each wear. The Day 1 cost for this device is seventy dollars and the lowest annual cost is $840.

One Health’s CGM, in contrast, requires only a single applicator, battery, and bluetooth transmitter. And it comes with more than a dozen sensors. The Day 1 cost? Just five dollars. And the lowest annual cost is sixty dollars — more than ninety-percent cheaper than the competition.

One Health’s device is pain-free and needle-free. It features a proprietary dicing technique that creates a clean, durable needle shape and has silicon oxide insulation for reducing interference and offering more accurate sensing.

The device senses glucose for those with diabetes, lactic acid for performance athletes, and urea for those with chronic kidney disease.

There’s also an Artificial Intelligence component to the CGM. AI informs actions and improves outcomes. It gives recommendations and learns a user’s habits and normal levels. One Health’s trove of data consists of more than sixty billion real-time contextual data points already collected.

One Health has been granted more than fifty patents and has forty-one others pending. It has demonstrated the performance of its CGM with more than 1,500 hours of clinical data. In one test, patients wore the device for twenty-four hours with successful results in terms of skin adhesion, data transmission, and battery life.

One Health’s investors include RRE, Box Group, FJ Labs, True Ventures, and First Round Capital. The company is conducting feasibility studies in 2024 and 2025 with plans for submission with the Food & Drug Administration in 2026.

Once launched, the company projects to bring in $250 million in revenue in the first two years and one billion dollars within the first five years. Its $250 million projection is based on 230,000 users in the U.S. and forty-five-percent gross margins, and its billion-dollar projection is based on 980,000 U.S. users and sixty-percent gross margins.

Notably, One Health’s team has an impressive track record. Founder Jeff Dachis co-founded Razorfish, a web-development company that went public in 1999 and was acquired by Microsoft in 2007 as part of a six-billion-dollar deal to acquire its parent company.

He also founded One Drop, a diabetes-management system that had more than 1.5 million users and grew to more than fifty million dollars in revenue in 2021. Dachis’s team includes experts in medical devices, AI, and data science, and has experience at Harvard, MIT, Roche, and Duke University.

Team Background

Jeff Dachis - Founder & CEO

Jeff is a successful entrepreneur who’s achieved multiple exits and has domain experience in the medical-device industry.

In addition to his role with One Health, he is Founder and CEO of One Drop, a diabetes-management system that reached fifty million dollars in revenue in 2021. Before that, he founded Dachis Group, a consulting business focused on social marketing.

Earlier, he co-founded Razorfish, a web-development company that went public in 1999 and was eventually acquired by Microsoft in a six-billion-dollar deal. Prior to start, he co-founded In Your Face, a marketing company.

Jeff earned a Bachelor’s degree from Purchase College and a Master’s degree from NYU.

Jon Brilliant - Chief Financial Officer

Jon has a track record of developing and launching diabetes devices. He also has extensive experience in the healthcare industry.

He was part of the founding team at Welldoc that became the first mobile app to obtain FDA clearance for medical purposes. He also co-founded Bigfoot Biomedical, a company seeking to change the standard of care for those requiring insulin.

He earned a Bachelor’s degree in Accounting from Penn State University and a Law degree from Duke University.

Dan Goldner - EVP of R&D

In addition to his role with One Health, Dan is Executive Vice President of R&D with One Drop, the healthtech company started by Jeff Dachis. Before that, he was a data scientist with Balance Position, a health and wellness company.

He has a background in education, having taught mathematics at Boston Public Schools. He was also a lead modeler for Ventana Systems, a consulting business, where he developed strategic models for NASA, the Federal Aviation Administration, and Fortune 50 companies.

Dan earned a Bachelor’s degree in Oceanography and Atmospheric Science from Harvard and a Ph.D. in Physical Oceanography from MIT.

Co-Investors